Presomen conti

Quick links to important sections

Presomen conti

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Presomen conti

Property Description
Active Ingredients Conjugated Estrogens, Medrogestone
Form Oral, Film-coated tablet
Pharmacological Class Hormone Replacement Therapy (HRT); Estrogen and Progestogen Combination
Common Purpose Alleviation of postmenopausal symptoms and uterine protection
Origin Derived (Estrogens) and Synthetic (Progestogen)

Classification and Identity: What Type of HRT is Presomen conti?

Presomen conti is an oral, combination product belonging to the Hormone Replacement Therapy (HRT) pharmacological class, a category clinically recognized for managing hormonal deficiency states. This medicine is specifically identified as a continuous combined regimen, a distinguishing feature of its formulation design. This classification means the formulation contains both active hormonal compounds, Conjugated Estrogens and Medrogestone, delivered daily without interruption, which is the standard approach for postmenopausal women who still have an intact uterus.

Core Composition: Conjugated Estrogens and Medrogestone

The medicine's composition is defined by its two active ingredients: Conjugated Estrogens (CEs) and the synthetic progestogen, Medrogestone. CEs are derived estrogenic compounds, providing the systemic estrogen component, while Medrogestone is a synthetic compound ensuring the necessary anti-estrogenic balance. This type of estrogen-progestogen combination is a widely established treatment option for menopausal symptoms.

General Purpose: Why is this Combination Medicine Used?

The general purpose of Presomen conti is to provide hormone restoration to help alleviate the wide array of discomforts associated with the postmenopausal state resulting from estrogen deficiency. The combined structure is essential because the inclusion of Medrogestone offers vital protection to the endometrium against the potential proliferative effects caused by the unopposed estrogen component, a fundamental safety principle in HRT, while the estrogen component works to mitigate symptoms such as vasomotor instability, commonly known as hot flashes.

Regulatory References

  1. NIH StatPearls: Hormone Replacement Therapy

What side effects are possible with Presomen conti?

Presomen conti, a continuous combined Hormone Replacement Therapy (HRT), has a safety profile officially documented by regulatory authorities (e.g., FDA, EMA), detailing potential adverse effects and safety constraints associated with systemic hormone exposure.

Frequency-Classified Adverse Reactions

Adverse effects are categorized by the likelihood of their occurrence, as defined in regulatory documents. Very common reactions, affecting 1 in 10 users or more, include headache and breast pain/tenderness. Common reactions, affecting 1 to 10 in 100 users, include dizziness, mood disturbances (such as depression), gastrointestinal effects (e.g., nausea, abdominal pain), weight changes, and fluid retention (oedema). Irregular bleeding or spotting is also a common occurrence, particularly during the initial months of treatment.


Serious Safety Considerations

Regulatory agencies highlight specific serious adverse reactions associated with combination HRT use. These include an increased risk of venous thromboembolism (VTE), such as deep vein thrombosis and pulmonary embolism, as well as arterial thromboembolic events (stroke and myocardial infarction). The risk of certain malignancies, including breast cancer and ovarian cancer, is also associated with the duration of use. For women aged 65 and older, initiation of combined HRT is linked to an increased risk of developing dementia.


Safety Constraints and Patterns

The medicine is formally contraindicated in patients with severe hepatic impairment (liver disease) and those with a history of or current thromboembolic disease or hormone-dependent cancers. Safety data notes that risks related to VTE and cancer generally increase with long-term exposure (typically over 5 years).

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents define the overdose profile for the active components in Presomen conti based on expected signs of estrogen excess and required emergency protocols. Exposure to a higher-than-prescribed dose may result in specific clinical manifestations, which necessitate immediate regulatory-mandated action.

Category Documented Clinical Manifestations
Gastrointestinal Effects Nausea, Vomiting, Abdominal pain
Systemic Effects Drowsiness, Fatigue
Hormonal Effects Breast tenderness
Population-Specific Note Withdrawal bleeding may occur in women

Emergency Action and Required Management

Regulatory guidance mandates that individuals seek emergency medical attention or contact the Poison Help line immediately upon suspecting an overdose. This requirement ensures that clinical evaluation can occur swiftly and that the appropriate supportive measures are instituted.

The management protocol, as defined in official prescribing information, consists of the discontinuation of therapy followed by the institution of appropriate symptomatic and supportive care. This standardized procedure is required because there is no specific antidote documented to reverse the effects of an acute overdose. Seeking urgent medical help is essential to manage the situation and address all documented physical manifestations of hormonal excess as described in regulatory text.

Therapeutic Uses of Presomen conti

Presomen conti is a therapeutic option used for Hormone Replacement Therapy (HRT) to address specific concerns associated with menopause.

Quick Facts

  • Relief of vasomotor symptoms: Assists in managing moderate to severe hot flashes and night sweats.
  • Management of urogenital atrophy: Used to address symptoms related to vulvar and vaginal changes.
  • Prevention of postmenopausal bone loss: Contributes to the reduction of a woman’s risk of osteoporosis.

This medication is approved to provide relief from moderate to severe vasomotor symptoms (such as hot flashes) that occur due to estrogen decline after menopause. It is generally initiated when these symptoms significantly impact a patient's quality of life and non-hormonal approaches are not suitable.

In addition, it offers support for managing symptoms of vulvar and vaginal atrophy, which can include dryness and discomfort. For appropriate individuals, it is also indicated for the prevention of postmenopausal osteoporosis in those who are at high risk of fracture and when other pharmacological agents are not considered adequate. These indications describe the established therapeutic role of this medication.

Eligibility and Restrictions for Use

Who can and cannot use Presomen conti?

The eligibility for Presomen conti (Conjugated Estrogens/Medrogestone) is strictly defined by official regulatory criteria, focusing on hormonal status and pre-existing health conditions.


Approved and Restricted Populations

  • Primary Eligibility: The medicine is intended solely for postmenopausal women with an intact uterus who require continuous combined hormone therapy. Use is exclusively for adults.
  • Pregnancy and Lactation: Use is contraindicated during pregnancy and not recommended during breastfeeding.

Absolute Contraindications (Must Not Use)

Presomen conti is strictly prohibited for individuals with:

  • An active or history of Venous or Arterial Thromboembolic Disease (e.g., blood clots, stroke, heart attack).
  • Known or Suspected Estrogen- or Progestogen-Dependent Malignant Tumors (e.g., breast or endometrial cancer).
  • Severe liver dysfunction or undiagnosed abnormal genital bleeding.

Age-Related and Conditional Limitations

  • Pediatric Use: The medicine is not indicated for children or adolescents.
  • Geriatric Use: Regulatory documents indicate a special caution for women 65 years of age and older due to an observed increased risk of probable dementia.
  • Comorbidity Restrictions: Caution is required for patients with pre-existing conditions like severe renal impairment or a history of endometriosis.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Presomen conti (Conjugated Estrogens, Medrogestone) exhibits specific, documented interaction patterns primarily through the pharmacokinetic alteration of its hormone components. These interactions are categorized by their effect on drug exposure and pharmacodynamic outcomes, as stated in regulatory prescribing information.


Pharmacokinetic and Metabolic Interactions

Co-administration with agents that affect the Cytochrome P450 3A4 (CYP3A4) enzyme system can modify the concentration of the hormones. CYP3A4 inducers (e.g., Rifampin, Carbamazepine, Phenytoin) are documented to decrease the plasma concentration of both the estrogen and progestogen components. Conversely, strong CYP3A4 inhibitors (e.g., Ketoconazole, Itraconazole) may increase the plasma concentration of the hormone components. The anticonvulsant Aminoglutethimide is specifically noted to depress the bioavailability of the progestogen component.


Pharmacodynamic and Substance Interactions

  • Thyroid Hormones: The estrogen component is documented to increase the plasma levels of Thyroid-Binding Globulin (TBG), which can necessitate monitoring and potential adjustment of thyroid replacement therapy (e.g., Levothyroxine).
  • Corticosteroids: Estrogens are documented to decrease the metabolic clearance of corticosteroids, resulting in an increased systemic exposure of the corticosteroid.
  • Herbal Products/Foods: The herbal product St. John's Wort is a documented CYP3A4 inducer, and Grapefruit Juice is documented as a CYP3A4 inhibitor, both carrying the risk of altering hormone exposure.

Interaction-Related Restrictions

Population-Specific Note: The product is contraindicated in patients with active or chronic liver dysfunction, reflecting a restriction related to the altered metabolism and clearance of the hormonal components in this specific patient population.

Mechanism of Action

The action of Presomen conti is achieved through the interdependent synergy of its two hormonal components, each targeting distinct nuclear receptors to elicit systemic effects while enforcing local tissue differentiation.

Modulation of Central and Peripheral ER Pathways

The Conjugated Estrogens component acts as an agonist on Estrogen Receptors ( ERalpha and ERbeta) in various tissues, including the hypothalamus. This molecular mechanism modulates the central control of body temperature, which leads to stabilized hypothalamic signaling related to vasomotor function, and simultaneously inhibits bone resorption by controlling the activity of bone cells, thereby modulating the bone turnover rate by inhibiting osteoclast activity.

Endometrial Anti-proliferative Mechanism

The Medrogestone component acts as an agonist on Progesterone Receptors ( PR) highly expressed in the uterine lining (endometrium). This activation triggers a gene-mediated cascade that functionally opposes the growth-stimulating signal of the estrogen component, shifting the tissue to a stable, secretory state that enforces an anti-proliferative signal in the endometrium through localized PR agonism.

Both components operate via the genomic pathway, which requires modulating gene transcription within the cell nucleus. This dictates that the modulation of systemic ER pathways and localized PR pathways develops gradually as new regulatory proteins are synthesized and downstream cascades are initiated.

Dosage and Administration Information

Presomen conti is administered via the oral route as a fixed-dose combination tablet. The operational structure of this medicine is defined by its continuous combined regimen, which requires the ingestion of one tablet once daily without interruption. This schedule ensures that both the Conjugated Estrogens and the progestogen, Medrogestone, are delivered continuously throughout the month.

The medicine is used at the lowest effective dose for the shortest duration consistent with the treatment goals, a principle that involves periodic reassessment by a healthcare professional to confirm the ongoing need for the medicine. Regarding intake logistics, the tablet may be taken with or without food and must be swallowed whole, preserving the integrity of the fixed dose.

In cases where a dose is forgotten, it is typically taken as soon as the omission is noted. If it is almost time for the subsequent dose, the missed dose is skipped, as it is a standard precaution to never take a double dose to compensate. When transitioning from a different continuous combined HRT, treatment may be initiated on any convenient day.

Recent Clinical Evidence

Presomen conti: Recent Clinical Evidence

Evidence Examining Vasomotor Symptoms

Studies exploring how symptoms change over time were conducted during periods of increased symptom activity in postmenopausal women. The evidence base includes Randomized Controlled Trials (RCTs) and comparative clinical trials where regimens like Presomen conti were observed against either an inactive treatment (placebo) or other active treatment regimens. Findings describe the patterns observed in the measurements of frequency and intensity of vasomotor episodes. Long-term data from broader research may not be directly applicable to this specific combination, and certainty remains low regarding extrapolation, as the most extensive data available for the general hormonal therapy class often uses a related but different progestogen component.

Evidence Examining Urogenital Atrophy

This evidence is derived largely from studies where the estrogen component, Conjugated Estrogens (CEs), was studied for outcomes related to inflammatory or irritative states. Research examined outcomes related to systemic or functional imbalance and patient-reported outcomes describing perceived discomfort. Systematic reviews and comparative studies have explored the effect of systemic estrogen on vulvar and vaginal tissues. Studies monitored patient-reported outcomes describing perceived discomfort, such as dryness and irritation. Comparative evidence is also lacking when trying to assess how this systemic approach compares directly to non-systemic, localized treatments for urogenital outcomes.

Evidence Examining Postmenopausal Bone Loss

This combination was evaluated in Randomized Controlled Trials and prospective comparative studies exploring outcomes related to bone loss. Research examined measures of Bone Mineral Density (BMD) at critical sites, such as the hip and spine. Research provides insight into patterns in BMD measurements in the observed populations over study durations typically lasting one to two years. Long-term effects are not fully established, as research primarily relies on BMD measurements, which serves as a surrogate outcome. Dedicated research focusing on actual fracture incidence for this specific CEs/Medrogestone combination is limited, meaning long-term outcomes are not well characterized.

Frequently Asked Questions (FAQ)

Common questions about Presomen conti (FAQ)

Q: Is Presomen conti the same as other hormone replacement therapies (HRT)?

Presomen conti belongs to the broad category of Hormone Replacement Therapy (HRT), but it is a distinct formulation. It is officially described as a continuous combined regimen, which means it delivers two active ingredients, Conjugated Estrogens and Medrogestone, every day without a break. Other HRT products may use different active hormones or different treatment schedules, making this specific combination unique.


Q: How long does it typically take before I start to feel the effects of the medicine?

The official mechanism of action indicates that the medicine works by modulating gene transcription inside cells. Because this process of action develops gradually, the modulation of systemic effects develops gradually as new regulatory proteins are synthesized and downstream cascades are initiated.


Q: Is Presomen conti suitable for use if I have a history of high blood pressure?

High blood pressure (hypertension) is often listed in official warnings for hormone therapy as a condition that requires caution and close monitoring by a healthcare professional. Estrogen use can increase the risk for serious problems like stroke, and this risk is generally considered greater if a person has pre-existing high blood pressure.


Q: Are there any common foods or drinks that might interact with this medicine?

Regulatory information specifically mentions grapefruit juice as a substance to be cautious of, as it may alter the hormone concentration in the body. Other foods are not specifically mentioned. The tablet may generally be taken with or without food. It is important for patients to review specific information regarding any dietary restrictions with a health professional.


Q: Is it required to take caution with Presomen conti if I am also taking vitamins or herbal supplements?

Official information explicitly names the herbal product St. John’s Wort as a substance that may decrease the effectiveness of the hormone components. Because of the potential for other interactions, patients are advised to review the full interaction profile of all vitamins and supplements with a health professional.


Q: What is the maximum duration of treatment with Presomen conti described in regulatory documents?

Regulatory guidance emphasizes that the medicine should be used at the lowest effective dose for the shortest duration consistent with treatment goals. Official safety information notes that risks related to blood clots and cancer generally increase with long-term exposure, typically defined as over 5 years of continuous use.


Q: Why might a doctor prescribe this specific type of HRT instead of another?

This specific continuous combined regimen is designed primarily for postmenopausal women with an intact uterus who are seeking modulation of their symptoms. The inclusion of the progestogen, Medrogestone, is essential to provide necessary safety protection to the uterine lining (endometrium) against the proliferative effects of the estrogen component.


Q: How often do I need to see my doctor for check-ups while on this medication?

Official regulatory guidance requires a periodic reassessment to confirm the ongoing need for the medicine. This monitoring often includes a discussion with a prescriber about necessary physical examinations and screenings. The specific frequency and procedures are determined during the periodic reassessment with a prescriber.


Q: If I have a mild side effect, is it something that usually goes away on its own?

Regulatory documents indicate that common side effects, especially irregular bleeding or spotting, tend to occur more often during the initial months of treatment. Official information does not provide a fixed timeline or guarantee that any specific mild side effect will resolve on its own.


Q: Does smoking affect how Presomen conti works?

Official regulatory warnings for hormone therapy state that smoking cigarettes can increase the risk of serious side effects. Specifically, smoking is associated with an increased risk of severe events like blood clots, stroke, or heart attack, and this risk is greater for individuals who smoke while using the medicine.


Q: Is it described in official sources that Presomen conti can help with hot flashes specifically?

Yes. The medicine is indicated for the alleviation of discomforts associated with the postmenopausal state. Official documents describe that the estrogen component acts to stabilize signaling related to vasomotor function, which is the mechanism linked to the modulation of symptoms commonly known as hot flashes.


Q: Does Presomen conti affect my risk of developing certain cancers?

Official safety information indicates an increased risk of certain malignancies, specifically breast cancer and ovarian cancer, associated with the duration of use of combination HRT. Furthermore, the medicine is strictly prohibited for individuals with known or suspected hormone-dependent malignant tumors.


Q: What are the less common, but serious, side effects associated with Presomen conti?

While classified as less common in frequency, regulatory documents highlight serious adverse reactions. These include an increased risk of venous and arterial thromboembolic events (such as blood clots, stroke, or heart attack). Additionally, for women aged 65 and older, there is an increased risk of developing probable dementia associated with starting this type of combined hormone therapy.


Q: Will Presomen conti interfere with my blood sugar levels if I am pre-diabetic?

Diabetes mellitus is listed in official documents as a pre-existing condition that requires caution and careful monitoring when starting hormone therapy. Estrogens are noted to possibly impair glucose tolerance in some patients, suggesting a potential for effects on blood sugar levels.


Q: What are the differences between Presomen conti and just taking estrogen alone?

The key difference is that Presomen conti contains the progestogen Medrogestone along with estrogen. Taking estrogen alone (unopposed estrogen) is associated with an increased risk of developing endometrial hyperplasia and endometrial cancer in women who still have an intact uterus. The progestogen component is included for the fundamental safety purpose of providing protection to the uterine lining.


Q: What evidence exists about Presomen conti and cognitive function?

Regulatory information includes a specific caution related to cognitive health for older users. It notes an observed increased risk of developing probable dementia in women 65 years of age and older who initiate combined hormone therapy.


Q: Can men use Presomen conti for any medical conditions?

Presomen conti is formally indicated only for postmenopausal women with an intact uterus. Based on the official prescribing information, it is not indicated or approved for use by men for any medical conditions.


Q: Are there any specific warnings about driving or operating machinery while on Presomen conti?

Official side effect information lists common reactions such as dizziness and mood disturbances. Side effects of this type may affect the ability to drive or operate machinery. It is important for patients to review the full patient information leaflet regarding such activities.


Q: Does alcohol consumption change the effectiveness or safety of Presomen conti?

Official patient information often suggests that the use of alcohol be discussed with a health professional. Generally, hormone replacement therapies carry warnings that emphasize that the risk of serious effects, such as stroke or heart attack, may be greater if a patient has other conditions often related to or exacerbated by high alcohol intake.


Q: Is a physical examination required before starting Presomen conti?

Regulatory guidance requires regular checks on patient progress and discussion of the need for regular breast and pelvic exams and mammograms with a health professional. This process implies that a physical examination is part of the initial assessment and ongoing monitoring of the medicine.


Q: Can Presomen conti affect vision or eye health?

Official warnings for estrogen-containing products sometimes advise checking with a health professional right away if a sudden loss of vision or any change in vision occurs. This indicates that vision changes are a possibility that should be monitored.


Q: Are there any specific times of day that are better for taking Presomen conti?

Official instructions state that the medicine should be taken once daily at roughly the same time each day. However, regulatory documents do not preferentially recommend a specific time of day (such as morning versus evening) for the tablet intake.

How should Presomen conti be stored and disposed of?

Storage and Handling Requirements

Presomen conti tablets must be stored strictly according to the conditions defined in the official labeling to ensure the stability of the active ingredients.

  • Required Temperature: Store at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F). The product must not be frozen.
  • Protection Conditions: The tablets must be protected from heat, moisture, and direct light. Always keep the medicine in its original, tightly closed container.
  • Child Safety: This medication must be stored securely, out of the sight and reach of children.

Disposal Instructions

Unused, expired, or unwanted Presomen conti must be disposed of according to local and national regulations for pharmaceutical waste. Do not discard the tablets in household trash or flush them down the toilet. Ask a pharmacist or healthcare professional for guidance on proper disposal procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Presomen conti found in:

A-Z Index: